Alcoholic liver disease

American Journal of Gastroenterology

Volumn 105, Issue 1, 2010, Pages 14-32

  Oshea, Robert S ^a   Dasarathy, Srinivasan ^a   McCullough, Arthur J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALCOHOL; ALPHA TOCOPHEROL; AMLODIPINE; ANABOLIC AGENT; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; ETANERCEPT; GLUCAGON; INFLIXIMAB; MISOPROSTOL; OXANDROLONE; PARACETAMOL; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE INHIBITOR; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; PROPYLTHIOURACIL; S ADENOSYLMETHIONINE; SILYMARIN; STEROID; TESTOSTERONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALCOHOLISM; ALGORITHM; ALTERNATIVE MEDICINE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUING EDUCATION; DIAGNOSTIC IMAGING; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRINKING BEHAVIOR; DRUG DOSE REDUCTION; DRUG OVERDOSE; GENETIC PREDISPOSITION; HEPATIC ENCEPHALOPATHY; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER REGENERATION; LIVER TRANSPLANTATION; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SCREENING TEST; STEROID THERAPY; ULTRASOUND;

EVIDENCE-BASED MEDICINE; HUMANS; LIVER DISEASES, ALCOHOLIC; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; WORLD HEALTH;

EID: 73849098307     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.593     Document Type: Review

References (276)

1. Eddy DM. A Manual For Assessing Health Practices and Designing Practice Guidelines: Te Explicit Approach. American College of Physicians: Philadelphia, 1992. American Gastoenterological Association. Policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925-926
2. Methodology Manual for ACC/AHA Guideline Writing Committees: Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines April 2006, 2006.
3. Shifman R N, Shekelle P, Overhage JM et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493-498
4. Patrick CH. Alcohol, Culture, and Society. Duke University Press: Durham, 1952.
5. Mandayam S, Jamal MM, Morgan TR. Epidemiology oflalcoholic liver disease. Semin Liver Dis 2004;24:217-232
6. Welte J, Barnes G, Wieczorek W et al. Alcohol and gambling pathology among U.S. adults: prevalence, demographic patterns and comorbidity. J Stud Alcohol 2001;62:706-712
7. Caetano R, Tam T, Greenfeld Thet al. DSM-IV alcohol dependence and drinking in the U.S. population: a risk analysis. Ann Epidemiol 1997;7:542-549
8. Tam T W, Midanik L T. The effect of screening on prevalence estimates oflalcohol dependence and social consequences. J Stud Alcohol 2000;61:617-621
9. Greenffeld TK, Midanik LT, Rogers JD. A 10-year national trend study oflalcohol consumption, 1984-1995: is the period of declining drinking over? Am J Public Health 2000; 90: 47-52.
10. Hasin D, Paykin A, Meydan J et al. Withdrawal and tolerance: prognostic signifcance in DSM-IV alcohol dependence. J Stud Alcohol 2000;61:431-438
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn., American Psychiatric Association: Washington, DC, 1994.
12. Chick J, Erickson CK. Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Alcohol Clin Exp Res 1996;20:391-402. (Pubitemid 26119635)
13. Kitchens JM. Does this patient have an alcohol problem? JAMA 1994;272:1782-1787
14. Grant B F, Harford T C, Dawson D A et al. Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992 Alcohol Health Res World 1992;18:243-248
15. National Institute of Health (US); National Institute on Alcohol Abuse and Alcoholism (US); CSR, Incorporated. Alcohol Use and Alcohol Use Disorders in the United States: Main Findings from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions ( NESARC ). National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD, 2006.
16. Yoon YH, Yi HY. Surveillance report #75: liver cirrhosis mortality in the United States, 1970 - 2003
17. National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD, 2006.
18. Becker U, Gronbaek M, Johansen D et al. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002;35:868-875
19. Pelletier S, Vaucher E, Aider R et al. Wine consumption is not associated with a decreased risk oflalcoholic cirrhosis in heavy drinkers. Alcohol Alcohol 2002;37:618-621
20. Corrao G, Ferrari P, Zambon A et al. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol 1997;58:486-494
21. Midanik L. The validity of self-reported alcohol consumption and alcohol problems: a literature review. Br J Addict 1982;77:357-382
22. World Health Organization. Global Status Report on Alcohol 2004-2004. World Health Organization: Geneva.
23. Ezzati M, Lopez A, Rodgers A, et al., The Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-1360
24. Lefowitch JH. Morphology oflalcoholic liver disease. Clin Liver Dis 2005;9:37-53.
25. Mendez-Sanchez N, Meda-Valdes P, Uribe M. Alcoholic liver disease. An update. Ann Hepatol 2005;4:32-42.
26. MacSween RN, Burt AD. Histologic spectrum oflalcoholic liver disease. Semin Liver Dis 1986;6:221-232
27. Crabb DW. Pathogenesis oflalcoholic liver disease: newer mechanisms of injury. Keio J Med 1999;48:184-188
28. Lieber C S, Jones D P, Decarli L M. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965; 44: 1009-1021
29. Mendenhall CL. Anabolic steroid therapy as an adjunct to diet in alcoholic hepatic steatosis. Am J Dig Dis 1968;13:783-791
30. Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore) 1962; 41: 249-276
31. Sorensen T I, Orholm M, Bentsen K D et al. Prospective evaluation oflalcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984; 2: 241-244
32. Teli M R, Day C P, Burt A D et al. Determinants of progression to cirrhosis or fbrosis in pure alcoholic fatty liver. Lancet 1995;346:987-990
33. Worner T M, Lieber C S. Perivenular fbrosis as precursor lesion of cirrhosis. JAMA 1985;254:627-630
34. Savolainen V, Perola M, Lalu K et al. E arly p eriven u lar f brogenesis--precirrhotic lesions among moderate alcohol consumers and chronic alcoholics. J Hepatol 1995; 23: 524-531
35. Nakano M, Worner T M, Lieber C S. Perivenular fbrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology 1982;83:777-785
36. MacSween RN, Scott AR. Hepatic cirrhosis: a clinico-pathological review of 520 cases. J Clin Pathol 1973; 26: 936-942
37. Orrego H, Blake J E, Blendis L M et al. Prognosis oflalcoholic cirrhosis in the presence and absence oflalcoholic hepatitis. Gastroenterology 1987;92:208-214
38. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981; 1: 707-711
39. Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res 1991; 15: 45-66.
40. Christoffersen P, Nielsen K. Histological changes in human liver biopsies from chronic alcoholics. Acta Pathol Microbiol Scand A 1972;80:557-565
41. Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981; 10: 417-441
42. Trabut J B, Plat A, Tepot V et al. Influence of liver biopsy on abstinence in alcohol-dependent patients. Alcohol Alcohol 2008;43:559-563
43. Alexander JF, Lischner MW, Galambos JT. Natural history oflalcoholic hepatitis. II. Te long-term prognosis. Am J Gastroenterol 1971;56:515-525
44. Bird GL, Williams R. Factors determining cirrhosis in alcoholic liver disease. Mol Aspects Med 1988;10:97-105. (Pubitemid 18228544)
45. Galambos J T. Natural history oflalcoholic hepatitis. Histological changes. Gastroenterology 1972;63:1026-1035
46. Savolainen V T, Liesto K, Mannikko A et al. Alcohol consumption and alcoholic liver disease: evidence ofla threshold level offeffects offethanol. Alcohol Clin Exp Res 1993;17:1112-1117
47. Becker U, Deis A, Sorensen T I et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996;23:1025-1029
48. Kamper-Jorgensen M, Gronbaek M, Tolstrup J et al. Alcohol and cirrhosis: dose--response or threshold efect? J Hepatol 2004;41:25-30.
49. Ramstedt M. Per capita alcohol consumption and liver cirrhosis mortality in 14 European countries. Addiction 2001; 96 (Suppl 1): S19-33.
50. Bellentani S, Saccoccio G, Costa G et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Te Dionysos Study Group. Gut 1997;41:845-850
51. Day CP. Who gets alcoholic liver disease: nature or nurture? J R Coll Physicians Lond 2000;34:557-562
52. Lu X L, Luo J Y, Tao M et al. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004;10:2423-2426
53. Wechsler H, Austin SB. Binge drinking: the f ve/four measure. J Stud Alcohol 1998;59:122-124
54. Barrio E, Tome S, Rodriguez I et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28: 131-136
55. Sato N, Lindros K O, Baraona E et al. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 2001; 25: 40S-5S.
56. Baraona E, Abittan C S, Dohmen K et al. Gender differences in pharmacoki-netics oflalcohol. Alcohol Clin Exp Res 2001; 25: 502-507
57. Frezza M,di P C, Pozzato G et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990;322:95-99
58. Lelbach WK. Epidemiology oflalcoholic liver disease. Prog Liver Dis 1976;5:494-515.
59. Lelbach WK. Quantitative aspects of drinking in alcoholic liver cirrhosis. In Khanna JM, Israel Y, Kalant H (eds). Alcoholic Liver Pathology. Volume Toronto. Alcoholism and Drug Addiction Research Foundation of Ontario: Toronto, 1975, 118.
60. Stewart SH. Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. Arch Intern Med 2002;162:2236-2239
61. Stinson F S, Grant B F, Dufour M C. The critical dimension offethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 2001;25:1181-1187
62. Wickramasinghe SN, Corridan B, Izaguirre J et al. Ethnic differences in the biological consequences oflalcohol abuse: a comparison between south Asian and European males. Alcohol Alcohol 1995;30:675-680
63. Mendenhall C, Roselle GA, Gartside P et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995;19:635-641
64. Leevy CM, Moroianu SA. Nutritional aspects oflalcoholic liver disease. Clin Liver Dis 2005;9:67-81.
65. Mezey E. Dietary fat and alcoholic liver disease. Hepatology 1998;28:901-905
66. Iturriaga H, Bunout D, Hirsch S et al. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 1988;47:235-238
67. Naveau S, Giraud V, Borotto E et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108-111
68. Uhl G R, Liu Q R, Walther D et al. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucle-otide polymorphisms. Am J Hum Genet 2001; 69: 1290-1300
69. Brown K. Alcohol hepatotoxicity: a genotypic predisposition? Am J Gastro-enterol 1992;87:677-678
70. Day CP, Bassendine MF. Genetic predisposition to alcoholic liver disease. Gut 1992;33:1444-1447
71. Goodwin D W, Schulsinger F, Hermansen L et al. Alcohol problems in adoptees raised apart from alcoholic biological parents. Arch Gen Psychiatry 1973;28:238-243
72. Kaprio J, Koskenvuo M, Langinvainio H et al. Social and genetic influences on drinking patterns ofladult men: a study of 5,638 Finnish twin brothers. Alcohol Alcohol Suppl 1987;1:373-377
73. Reed T, Page W F, Viken R J et al. Genetic predisposition to organ-specific endpoints oflalcoholism. Alcohol Clin Exp Res 1996;20:1528-1533
74. Mc Clain C J, Song Z, Barve S S et al. Recent advances in alcoholic liver disease. I V. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004;287:G497-502.
75. Monzoni A, Masutti F, Saccoccio G et al. Genetic determinants offethanol-induced liver damage. Mol Med 2001;7:255-262
76. Degos F. Hepatitis C and alcohol. J Hepatol 1999;31 (Suppl 1): 113-118
77. Monto A, Patel K, Bostrom A et al. Risks ofla range oflalcohol intake on hepatitis C-related fbrosis. Hepatology 2004;39:826-834
78. Befrits R, Hedman M, Blomquist L et al. Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995;30:1113-1118
79. Harris DR, Gonin R, Alter HJ et al. The relationship oflacute transfusion-associated hepatitis to the development of cirrhosis in the presence oflalcohol abuse. Ann Intern Med 2001;134:120-124
80. Levitsky J, Mailliard ME. Diagnosis and therapy oflalcoholic liver disease. Semin Liver Dis 2004;24:233-247
81. Grant BF. Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample. J Stud Alcohol 1997;58:365-371
82. Eckardt MJ, Rawlings RR, Martin PR. Biological correlates and detection oflalcohol abuse and alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:135-144
83. Mc Quade W H, Levy SM, Yanek L R et al. Detecting symptoms oflalcohol abuse in primary care settings. Arch Fam Med 2000;9:814-821
84. D'Amico EJ, Paddock SM, Burnam A et al. Identification ofland guidance for problem drinking by general medical providers: results from a national survey. Med Care 2005;43:229-236
85. Sharpe PC. Biochemical detection and monitoring oflalcohol abuse and abstinence. Ann Clin Biochem 2001;38:652-664
86. Umbricht-Schneiter A, Santora P, Moore R D. Alcohol abuse: comparison of two methods for assessing its prevalence and associated morbidity in hospitalized patients. Am J Med 1991; 91: 110-118
87. Moore R D, Bone L R, Geller G et al. Prevalence, detection, and treatment oflalcoholism in hospitalized patients. JAMA 1989;261:403-407
88. Prytz H, Melin T. Identification oflalcoholic liver disease or hidden alcohol abuse in patients with elevated liver enzymes. J Intern Med 1993; 233: 21-26
89. Girela E, Villanueva E, Hernandez-Cueto C et al. Comparison of the CAGE questionnaire vs. some biochemical markers in the diagnosis oflalcoholism. Alcohol Alcohol 1994;29:337-343
90. Levine J. The relative value of consultation, questionnaires and laboratory investigation in the identification offexcessive alcohol consumption. Alcohol Alcohol 1990; 25: 539-553
91. Helander A, Eriksson CJ. Laboratory tests for acute alcohol consumption: results of the WHO/ISBRA Study on State and Trait Markers oflalcohol Use and Dependence. Alcohol Clin Exp Res 2002;26:1070-1077
92. Aalto M, Seppa K. Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. Alcohol Alcohol 2005;40:520-523
93. Soderstrom CA, Smith GS, Kufera JA et al. The accuracy of the CAGE, the Brief Michigan Alcoholism Screening Test, and the Alcohol Use Disorders Identification Test in screening trauma center patients for alcoholism. J Trauma 1997;43:962-969
94. Skinner HA, Sheu WJ. Reliability oflalcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 1982;43:1157-1170
95. Aertgeerts B, Buntinx F, Kester A. The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis. J Clin Epidemiol 2004;57:30-39
96. Bataille V, Ruidavets JB, Arveiler D et al. Joint use of clinical parameters, biological markers and CAGE questionnaire for the identification of heavy drinkers in a large population-based sample. Alcohol Alcohol 2003; 38: 121-127
97. Saunders JB, Aasland O G, Babor T F et al. Developmentofthe Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993;88:791-804.
98. Fiellin DA, Reid MC, O'Connor PG. Screening for alcohol problems in primary care: a systematic review. Arch Intern Med 2000;160:1977-1989
99. MacKenzie D, Langa A, Brown TM. Identifying hazardous or harmful alcohol use in medical admissions: a comparison oflaudit, cage and brief mast. Alcohol Alcohol 1996;31:591-599
100. Bradley K A, Bush K R, McDonell M B et al. Screening for problem drinking: comparison of CAGE and AUDIT. J Gen Intern Med 1998;13:379-388
101. Steinbauer JR, Cantor SB, Holzer CE III et al. Ethnic and sex bias in primary care screening tests for alcohol use disorders. Ann Intern Med 1998;129:353-362
102. Helping Patients Who Drink Too Much: A Clinician's Guide. US Department of Health and Human Services, National Institute of Health, National Institute on Alcohol Abuse and Alcoholism, 2005
103. US Preventive Services Task Force (USPSTF). Screening and behavioral counselling interventions in primary care to reduce alcohol misuse. Recommendation Statement 2004.
104. Au D H, Kivlahan D R, Bryson C L et al.Alcohol screening scores and risk of hospitalizations for GI conditions in men. Alcohol Clin Exp Res 2007;31:443-451
105. Yersin B, Nicolet JF, Dercrey H et al. S creening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med 1995;155:1907-1911
106. Conigrave K M, Degenhardt L J, Whitfeld JB et al. CDT, GGT, and AST as markers oflalcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002;26:332-339
107. Sillanaukee P, Massot N, Jousilahti P et al. Dose response of laboratory markers to alcohol consumption in a general population. Am J Epidemiol 2000;152:747-751
108. Alte D, Luedemann J, Rose H J et al. Laboratory markers carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcohol Clin Exp Res 2004;28:931-940
109. Reynaud M, Schellenberg F, Loisequx-Meunier MN et al. Objective diagnosis oflalcohol abuse: compared values of carbohydrate-deficient trans-ferrin (CDT), gamma-glutamyl transferase (GGT), and mean corpuscular volume (MCV). Alcohol Clin Exp Res 2000; 24: 1414-1419
110. Poynard T, Zourabichvili O, Hilpert G et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 1984;4:324-327
111. Naveau S, Poynard T, Abella A et al. Prognostic value of serum f bronectin concentration in alcoholic cirrhotic patients. Hepatology 1985;5:819-823
112. Chen J, Conigrave K M, Macaskill P et al. Combining carbohydrate- deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol Alcohol 2003;38:574-582
113. Hannuksela M L, Liisanantti M K, Nissinen A E et al. Biochemical markers oflalcoholism. Clin Chem Lab Med 2007;45:953-961
114. Hartmann S, Aradottir S, Graf M et al. Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-defcient transferrin. Addict Biol 2007;12:81-84
115. Bortolotti F, De PG, Tagliaro F. Carbohydrate-deficient transferrin (CDT) as a marker oflalcohol abuse: a critical review of the literature 2001-2005. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 841: 96-109.
116. Wurst F M, Alling C, Aradottir S et al. Emerging biomarkers: new directions and clinical applications. Alcohol Clin Exp Res 2005;29:465-473
117. Hock B, Schwarz M, Domke I et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005;100:1477-1486
118. Anttila P, Jarvi K, Latvala J et al. Biomarkers oflalcohol consumption in patients classiffed according to the degree of liver disease severity. Scand J Clin Lab Invest 2005;65:141-151
119. Center for Substance Abuse Treatment. The role of biomarkers in the treatment oflalcohol use disorders. Substance Abuse Treatment Advisory, Vol 5 ( 4 ), September 2006. Accessed online at: http://www.kap.samhsa.gov/products/ manuals/advisory/pdfs/0609-biomarkers.pdf.
120. Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment oflalcoholic liver disease. Mayo Clin Proc 2001;76:1021-1029
121. Nalpas B, Vassault A, Charpin S et al. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology 1986; 6: 608-614
122. Uchida T, Kao H, Quispe-Sjogren M et al. Alcoholic foamy degenera-tion--a pattern oflacute alcoholic injury of the liver. Gastroenterology 1983;84:683-692
123. Nanji A A, firench SW, Mendenhall C L. Serum aspartate amino transferase to alanine aminotransferase ratio in human and experimental alcoholic liver disease: relationship to histologic changes. Enzyme 1989;41:112-115
124. Cohen J A, Kaplan M M. The SGOT/SGPT ratio--an indicator oflalcoholic liver disease. Dig Dis Sci 1979;24:835-838
125. Niemela O. Biomarkers in alcoholism. Clin Chim Acta 2007;377:39-49.
126. Nyblom H Berggren U Balldin J et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking Alcohol Alcohol 2004 39 336-9
127. Nyblom H, Berggren U, Balldin J et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004;39:336-9. de BG, Graviss EA. A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Med Inform Decis Mak 2001;1:6.
128. Leung N W, flarrant P, Peters T J. Liver volume measurement by ultrasonography in normal subjects and alcoholic patients. J Hepatol 1986; 2: 157-164
129. Hamberg K J, Carstensen B, Sorensen T I et al.Accuracyofclinical diagnosis of cirrhosis among alcohol-abusing men. J Clin Epidemiol 1996;49:1295-1301
130. Cozzolino G, Francica G, Lonardo A et al. Variabilityofthe clinical and laboratory aspects in the presentation of chronic liver diseases in relation to their etiology. Analysis ofla case study and review of the literature. Minerva Med 1985;76:753-760
131. Orrego H, Israel Y, Blake J E et al. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983;3:896-905.
132. Espinoza P, Ducot B, Pelletier G et al. Interobserver agreement in the physical diagnosis oflalcoholic liver disease. Dig Dis Sci 1987;32:244-247
133. Goldstein LI. Enlarged, tortuous arteries and hepatic bruit. JAMA 1968;206:2518-2520
134. Han S H, Rice S, Cohen S M et al. Duplex Doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J Clin Gastroenterol 2002;34:573-577
135. Sherman H I, Hardison J E. The importance ofla coexistent hepatic rub and bruit. A clue to the diagnosis of cancer in the liver. JAMA 1979; 241: 1495.
136. Zoneraich S, Zoneraich O. Diagnostic significance oflabdominal arterial murmurs in liver and pancreatic disease. A phonoarteriographic study. Angiology 1971;22:197-205.
137. Naylor C D. The rational clinical examination. Physical examination of the liver. JAMA 1994;271:1859-1865
138. Klatsky AL, Chartier D, Udaltsova N et al. Alcohol drinking and risk of hospitalization for heart failure with and without associated coronary artery disease. Am J Cardiol 2005;96:346-351
139. Lazarevic A M, Nakatani S, Neskovic A N et al. Early changes in lef ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35: 1599-1606
140. Preedy V R, Adachi J, Ueno Y et al. Alcoholic skel et al muscle myopathy: def nitions, features, contribution of neuropathy, impact and diagnosis. Eur J Neurol 2001;8:677-687
141. Estruch R, Nicolas J M, Villegas E et al. Relationship between ethanol-re-lated diseases and nutritional status in chronically alcoholic men. Alcohol Alcohol 1993;28:543-550 (Pubitemid 23316907)
142. Anderson P, Cremona A, Paton A et al. The risk ofalcohol. Addiction 1993;88:1493-1508
143. Schiano T D, Bodian C, Schwartz M E et al. Accuracy and significance of computed tomographic scan assessment of hepatic volume in patients undergoing liver transplantation. Transplantation 2000;69:545-550
144. Bird GL. Investigation oflalcoholic liver disease. Baillieres Clin Gastroen-terol 1993;7:663-682
145. Vilgrain V. Ultrasound of difuse liver disease and portal hypertension. Eur Radiol 2001;11:1563-1577
146. Okazaki H, Ito K, Fujita Thet al. Discrimination oflalcoholic from virus-induced cirrhosis on MR imaging. Am J Roentgenol 2000;175:1677-1681
147. Awaya H, Mitchell D G, Kamishima Thet al. Cirrhosis: modiffed caudate-right lobe ratio. Radiology 2002;224:769-774
148. Levin DM, Baker AL, Riddell RH et al. Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med 1979;66:429-434
149. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:543-548
150. Hall PD. Pathological spectrum oflalcoholic liver disease. Alcohol Alcohol Suppl 1994;2:303-313
151. Mathurin P, Duchatelle V, Ramond M J et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110:1847-1853
152. Nissenbaum M, Chedid A, Mendenhall C et al. Prognostic significance of cholestatic alcoholic hepatitis. VA Cooperative Study Group #119. Dig Dis Sci 1990;35:891-896
153. Chedid A, Mendenhall C L, Tosch Thet al.Sign ificance of megamitochon-dria in alcoholic liver disease. Gastroenterology 1986;90:1858-1864
154. Tanaka T, Yabusako T, Yamashita Thet al. Contribution of hepatitis C virus to the progression oflalcoholic liver disease. Alcohol Clin Exp Res 2000;24:112S-6S.
155. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalco-holics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062
156. Mathurin P, Poynard T, Ramond M J et al. Interet delabiopsie hepatique pour la selection des sujets suspects d ' hepatitealcoolique aigue. Gastroen-terol Clin Biol 1992;16:A231.
157. Maddrey W C, Boitnott JK, Bedine M S et al. Corticosteroid therapy oflalcoholic hepatitis. Gastroenterology 1978;75:193-199
158. Carithers R L Jr, Herlong H F, Diehl A M et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110:685-690
159. Mathurin P, Abdelnour M, Ramond M J et al.Early changeinbilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003;38:1363-1369
160. Kamath P S, Wiesner R H, Malinchoc M et al.A modeltopredict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
161. Forrest E H, Evans C D, Stewart S et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-1179
162. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2.
163. Said A, Williams J, Holden J et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903.
164. Srikureja W, Kyulo N L, Runyon B A et al. MELD scoreisa better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005;42:700-706
165. Soultati A S, Dourakis SP, Alexopoulou A et al. Predicting utility ofla model for end stage liver disease in alcoholic liver disease. World J Gastroenterol 2006; 12: 4020-4025
166. Dunn W, Jamil L H, Brown L S et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41:353-358
167. Rincon D, Lo IO, Ripoll C et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Phar macol Ter 2007;25:841-848
168. Mookerjee RP, Malaki M, Davies NA et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007;45:62-71.
169. Sougioultzis S, Dalakas E, Hayes P C et al. Alcoholic hepatitis: from patho-genesis to treatment. Curr Med Res Opin 2005; 21: 1337-1346
170. Lieber CS. New concepts of the pathogenesis oflalcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep 2004; 6: 60-65
171. Pessione F, Ramond M J, Peters L et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect oflalcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 45-53.
172. Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981;80:1405-1409
173. Brunt PW, Kew MC, Scheuer PJ et al. Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut 1974;15:52-58
174. Luca A, Garcia-Pagan J C, Bosch J et al. Effects offethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterol-ogy 1997;112:1284-1289
175. Pares A, Caballeria J, Bruguera M et al. Histological course oflalcoholic hepatitis. Influence oflabstinence, sex and extent of hepatic damage. J Hepatol 1986; 2: 33-42.
176. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence oflalcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968;44:406-420
177. Veldt B J, Laine F, Guillygomarc'h A et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93-98
178. Kelly JP, Kaufman D W, Kof R S et al. Alcohol consumption and the risk of major upper gastrointestinal bleeding. Am J Gastroenterol 1995;90:1058-1064
179. Mackie J, Groves K, Hoyle A et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001;7:418-427
180. Miguet M, Monnet E, Vanlemmens C et al. Predictive factors oflalcohol relapse affer orthotopic liver transplantation for alcoholic liver disease. Gastroenterol Clin Biol 2004;28:845-851
181. Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? J Stud Alcohol 2001;62:211-220
182. Pharmacotherapy for Alcohol Dependence. Summary, Evidence Report/ Technology Assessment: Number 3, January 1999.
183. Agency for Health Care Policy and Research: Rockville, MD. http://www.ahrq.gov/clinic/epcsums/ alcosumm.htm.
184. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005. Art. No. CD001867.
185. Palmer A J, Neeser K, Weiss C et al. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol 2000;35:478-492
186. Mason BJ. Acamprosate in the treatment oflalcohol dependence. Expert Opin Pharmacother 2005;6:2103-2115
187. Anton R F, O 'Malley SS, Ciraulo D A et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017
188. Addolorato G, Leggio L, Ferrulli A et al. Effectiveness and safety of baclofen for maintenance oflalcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-1922
189. Galambos JT. Alcoholic hepatitis: its therapy and prognosis. Prog Liver Dis 1972;4:567-588
190. Chedid A, Mendenhall CL, Gartside P et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 1991;86:210-216
191. Saunders JB, Davis M, Williams R. Do women develop alcoholic liver disease more readily than men? Br Med J (Clin Res Ed) 1981;282:1140-1143
192. Kondili L A, Taliani G, Cerga G et al. Correlation oflalcohol consumption with liver histological features in non-cirrhotic patients. Eur J Gastroen-terol Hepatol 2005; 17: 155-159
193. Pendery ML, Maltzman IM, West LJ. Controlled drinking by alcoholics? New f ndings and a reevaluation ofla major afrmative study. Science 1982;217:169-175
194. Mezey E. Interaction between alcohol and nutrition in the pathogenesis oflalcoholic liver disease. Semin Liver Dis 1991;11:340-348
195. Mendenhall C L, Anderson S, Weesner R E et al.Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984;76:211-222
196. Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994; 19: 518-533
197. Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment oflacute alcoholic hepatitis. J Hepatol 1985; 1: 141-151
198. Cabre E, Rodriguez-Iglesias P, Caballeria J et al. Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000;32:36-42.
199. Foody W, Heuman D D, Mihas A A et al. Nutritional therapy for alcoholic hepatitis: new life for an old idea. Gastroenterology 2001; 120: 1053-1054
200. Plauth M, Cabre E, Riggio O et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006;25:285-294
201. Daures JP, Peray P, Bories P et al. Corticoid therapy in the treatment oflacute alcoholic hepatitis. Results ofla meta-analysis. Gastroenterol Clin Biol 1991;15:223-228
202. Reynolds T B, Benhamou JP, Blake J et al. Treatment oflalcoholic hepatitis. Gastroenterol Int 1989;2:208-216
203. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113:299-307.
204. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-118
205. Rambaldi A, Saconato HH, Christensen E et al. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178
206. Higgins J, Tompson S, Deeks J et al. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:51-61.
207. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008;27:625-650
208. Mathurin P, Mendenhall C L, Carithers R L Jr et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-487
209. Phillips M, Curtis H, Portmann B et al. Antioxidants vs. corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. J Hepatol 2006; 44: 784-790
210. O'Shea R, McCullough A J. Steroidsor cocktails for alcoholic hepatitis. J Hepatol 2006; 44: 633-636
211. Uribe M, Schalm S W, Summerskill W H et al. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut 1978;19:1131-1135
212. Louvet A, Naveau S, Abdelnour M et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348-1354
213. Akriviadis E, Botla R, Briggs W et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
214. Menon KV, Stadheim L, Kamath PS et al. A pilot study of the safety and tolerability offetanercept in patients with alcoholic hepatitis. Am J Gastro-enterol 2004;99:255-260
215. Spahr L, Rubbia-Brandt L, Frossard JL et al. Combinationofsteroids with inf iximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448-455
216. Naveau S, Chollet-Martin S, Dharancy S et al. A double-blind randomized controlled trial of inf iximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-1397
217. Mookerjee R P, Tilg H, Williams R et al. Infiximab and alcoholic hepatitis. Hepatology 2004; 40: 499-500.
218. Boetticher N C, Peine C J, Kwo P et al. A randomized, double-blinded, placebo-controlled multicenter trial offetanercept in the treatment oflalcoholic hepatitis. Gastroenterology 2008;135:1953-1960
219. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-in-duced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G583-9.
220. Louvet A, Diaz E, Dharancy S et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is ineficient in non-responders to corticosteroids. J Hepatol 2008;48:465-470
221. Bonkovsky H L, Fiellin D A, Smith G S et al. A randomized, controlled trial of treatment oflalcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 1991; 86: 1200-1208
222. Alvarez MA, Cabre E, Lorenzo-Zuniga V et al. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results ofla pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1375-1380
223. Kulkarni K, Tran T, Medrano M et al. The role of the discriminant factor in the assessment and treatment oflalcoholic hepatitis. J Clin Gastroenterol 2004;38:453-459
224. O'Shea R S, McCullough A J. Treatment oflalcoholic hepatitis. Clin Liver Dis 2005;9:103-134
225. Jalan R, Sen S, Steiner C et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003;38:24-31.
226. Wolf B, Machill K, Schumacher D et al. MARS dialysis in decompen-sated alcoholic liver disease: a single-center experience. Liver Transpl 2007;13:1189-1192
227. Tsuji Y, Kumashiro R, Ishii K et al. Severe alcoholic hepatitis successfully treated by leukocytapheresis: a case report. Alcohol Clin Exp Res 2003;27:26S-31S.
228. Okubo K, Yoshizawa K, Okiyama W et al. Severe alcoholic hepatitis with extremely high neutrophil count successfully treated by granulocytapher-esis. Intern Med 2006;45:155-158
229. Stickel F, Hoehn B, Schuppan D et al. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ter 2003;18:357-373
230. Marchesini G, Dioguardi FS, Bianchi GP et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92-101.
231. Hirsch S, Bunout D,dela M P et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. J Parenter Enteral Nutr 1993; 17: 119-124
232. Smith J, Horowitz J, Henderson J M et al. Enteral hyperalimentation in undernourished patients with cirrhosis and ascites. Am J Clin Nutr 1982;35:56-72.
233. Kearns P J, Young H, Garcia G et al. Accelerated improvement oflalcoholic liver disease with enteral nutrition. Gastroenterology 1992; 102: 200-205
234. Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutr Metab Care 1999; 2: 345-349
235. Swart G R, Zillikens M C,van Vuure JK et al.Effect ofla late evening meal on nitrogen balance in patients with cirrhosis of the liver. Br Med J 1989;299:1202-1203
236. Zillikens MC,vanden Berg JW, Wattimena JL et al. Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls. J Hepatol 1993;17:377-383
237. Mezey E. Commentary on the hypermetabolic state and the role of oxygen in alcohol-induced liver injury. Recent Dev Alcohol 1984;2:135-141
238. Orrego H, Blake JE, Blendis L M et al. Long-term treatment oflalcoholic liver disease with propylthiouracil. N Engl J Med 1987;317:1421-1427
239. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2002 Art. No. CD002800.
240. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002; 76: 1183S-7S.
241. Mato JM, Camara J, Fernandezde P J et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-1089
242. Martinez-Chantar M L, Garcia-Trevijano E R, Latasa M U et al. Importance ofla deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002; 76: 1177S-82S.
243. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006 Art. No. CD002235.
244. Kershenobich D, Uribe M, Suarez G I et al. Treatment of cirrhosis with col-chicine. A double-blind randomized trial. Gastroenterology 1979; 77: 532-536
245. Morgan T R, Weiss D G, Nemchausky B et al. Colchicine treatment oflalcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005;128:882-890
246. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver f-brosis and cirrhosis. Cochrane Database Syst Rev 2005 Art. No. CD002148.
247. Day CP. Apoptosis in alcoholic hepatitis: a novel therapeutic target? J Hepatol 2001;34:330-333
248. Austin A S, Mahida Y R, Clarke D et al. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ter 2004;19:79-88.
249. Yokota T, Oritani K, Takahashi I et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-1732
250. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflam-matory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350
251. Loguercio C, Federico A, Tuccillo C et al. Beneficial effects ofla probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005;39:540-543
252. Mullen KD, Dasarathy S. Potential new therapies for alcoholic liver disease. Clin Liver Dis 1998;2:851-881
253. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of sily-marin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-113
254. Rambaldi A, Jacobs BP, Iaquinto G et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroen-terol 2005;100:2583-2591
255. Burra P, Lucey MR. Liver transplantation in alcoholic patients. Transpl Int 2005;18:491-498
256. O'Grady JG. Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest!. Gut 2006;55:1529-1531
257. Lucey M R, Brown K A, Everson G Thet al. Minimal criteria for placement ofladults on the liver transplant waiting list: a report ofla national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation 1998;66:956-962
258. Perney P, Bismuth M, Sigaud H et al. Are preoperative patterns oflalcohol consumption predictive of relapse affer liver transplantation for alcoholic liver disease? Transpl Int 2005;18:1292-1297
259. Bellamy CO, DiMartini AM, Ruppert K et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001;72:619-626
260. Zetterman RK. Liver transplantation for alcoholic liver disease. Clin Liver Dis 2005;9:171-181
261. Newton SE. Recidivism and return to work posttransplant. Recipients with substance abuse histories. J Subst Abuse Treat 1999;17:103-108
262. Mathurin P. Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. Liver Transpl 2005; 11: S21-4.
263. Turner C. How much alcohol is in a 'standard drink'? An analysis of 125 studies. Br J Addict 1990;85:1171-1175
264. Brick J. Standardization oflalcohol calculations in research. Alcohol Clin Exp Res 2006;30:1276-1287
265. Ewing JA. Detecting alcoholism. Te CAGE questionnaire. JAMA 1984;252:1905-1907
266. Porter H P, Simon FIR, Pope C E et al. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971;284:1350-1355
267. Helman R A, Temko M H, Nye SW et al. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971;74:311-321
268. Campra JL, Hamlin E M Jr, Kirshbaum R J et al.P red n iso n e th erap y o flacute alcoholic hepatitis. Report ofla controlled trial. Ann Intern Med 1973;79:625-631
269. Blitzer B L, Mutchnick M G, Joshi P H et al. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977;22:477-484
270. Lesesne H R, Bozymski E M, flallon H J. Treatment oflalcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978;74:169-173
271. Shumaker JB, Resnick RH, Galambos JThet al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978;69:443-449
272. Depew W, Boyer T, Omata M et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980;78:524-529
273. Theodossi A, Eddleston A L, Williams R. Controlled trial of methylp red nisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23: 75-79
274. Mendenhall C L, Anderson S, Garcia-Pont P et al. Short-term an d lo n gterm survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984;311:1464-1470
275. Bories P, Guedj J Y, Mirouze D et al. Treatment oflacute alcoholic hepatitis with prednisolone. 45 patients. Presse Med 1987;16:769-772 (Pubitemid 17077442)
276. Ramond M J, Poynard T, Ruef B et al. A randomized trial of pred-nisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507-512